radoncreview's profile picture. Our mission is to create the most comprehensively updated Rad Onc reference and to make it available for free, forever, for all.

radoncreview_org

@radoncreview

Our mission is to create the most comprehensively updated Rad Onc reference and to make it available for free, forever, for all.

Pinned

Math checks out with absolute dose! HCC is a rather radiosensitive tumor. Interesting aside: A BED10 of >80 Gy with EBRT yields 80–90% local control. For context, 400 Gy in a single fraction equates to a BED10 of 16,400 Gy—yet the X-axis of this chart maxes out at 150 Gy. Of…

radoncreview's tweet image. Math checks out with absolute dose! HCC is a rather radiosensitive tumor. 

Interesting aside: A BED10 of >80 Gy with EBRT yields 80–90% local control.

For context, 400 Gy in a single fraction equates to a BED10 of 16,400 Gy—yet the X-axis of this chart maxes out at 150 Gy. Of…

Nope. You need 10% of that, in five fractions. ALARA.



radoncreview_org reposted

RadOncReview ftw again. Thank you @jryckman3 🙏. Incredible resource. GI highlights below. #ASTRO25

NiuSanford's tweet image. RadOncReview ftw again. Thank you @jryckman3 🙏. Incredible resource.

GI highlights below. #ASTRO25

Our “Best Of” #ASTRO25 abstract summary is out! 🦾🎯 Featuring plenaries, late-breaking abstracts, and select scientific highlights. I'm sure we missed plenty of gems - what would you add? 👇 bit.ly/BestOfASTRO25



The latest #ASTRO25 study dump now brings us to over 2,000 studies logged since May 2020. Happy studying and treating, and thank you for being part of this community! 🔗 bit.ly/RoROnDeck

radoncreview's tweet image. The latest #ASTRO25 study dump now brings us to over 2,000 studies logged since May 2020.

Happy studying and treating, and thank you for being part of this community!

🔗 bit.ly/RoROnDeck

Our “Best Of” #ASTRO25 abstract summary is out! 🦾🎯 Featuring plenaries, late-breaking abstracts, and select scientific highlights. I'm sure we missed plenty of gems - what would you add? 👇 bit.ly/BestOfASTRO25



Our “Best Of” #ASTRO25 abstract summary is out! 🦾🎯 Featuring plenaries, late-breaking abstracts, and select scientific highlights. I'm sure we missed plenty of gems - what would you add? 👇 bit.ly/BestOfASTRO25


radoncreview_org reposted

Check out the new updates to #RadOncCalc and @RadoncTables available now on all platforms (iOS, Android, web) Rad Onc Tables IOS ➡️ is.gd/tnqpTT Android ➡️ is.gd/dzc9xH Rad Onc Calc IOS ➡️ is.gd/txHOue Android ➡️ is.gd/HzIP5x


radoncreview_org reposted

Here is a provocative paper for stage III. This data is suggestive of Rituximab + RT being curative treatment, with none of the 11 patients who received peri-radiation Rituximab experiencing relapse. DLBCL-free survival is a patient-centric endpoint! ncbi.nlm.nih.gov/pubmed/32316464

radoncreview's tweet image. Here is a provocative paper for stage III.

This data is suggestive of Rituximab + RT being curative treatment, with none of the 11 patients who received peri-radiation Rituximab experiencing relapse.

DLBCL-free survival is a patient-centric endpoint!

ncbi.nlm.nih.gov/pubmed/32316464
radoncreview's tweet image. Here is a provocative paper for stage III.

This data is suggestive of Rituximab + RT being curative treatment, with none of the 11 patients who received peri-radiation Rituximab experiencing relapse.

DLBCL-free survival is a patient-centric endpoint!

ncbi.nlm.nih.gov/pubmed/32316464

radoncreview_org reposted

Rituximab does not decrease transformation to DLBCL. Adding targeted, modern radiotherapy may decreases this ~20% long term risk by an order of magnitude. DLBCL-free survival is a meaningful endpoint for patients. Teamwork is key! 🤝 #LYMSM sciencedirect.com/science/articl…

radoncreview's tweet image. Rituximab does not decrease transformation to DLBCL.

Adding targeted, modern radiotherapy may decreases this ~20% long term risk by an order of magnitude.

DLBCL-free survival is a meaningful endpoint for patients. 

Teamwork is key! 🤝 #LYMSM

sciencedirect.com/science/articl…
radoncreview's tweet image. Rituximab does not decrease transformation to DLBCL.

Adding targeted, modern radiotherapy may decreases this ~20% long term risk by an order of magnitude.

DLBCL-free survival is a meaningful endpoint for patients. 

Teamwork is key! 🤝 #LYMSM

sciencedirect.com/science/articl…
radoncreview's tweet image. Rituximab does not decrease transformation to DLBCL.

Adding targeted, modern radiotherapy may decreases this ~20% long term risk by an order of magnitude.

DLBCL-free survival is a meaningful endpoint for patients. 

Teamwork is key! 🤝 #LYMSM

sciencedirect.com/science/articl…

15-yr F/U of my fav study by Ardeshna et al.: W&W v Rx4 low tumor burden FL - median TTNT: NR in R maint, 14.8 yrs (!!!) in Rx4, 5.6 yrs in W&W - 34% of W&W cohort with no tx at 15 yrs! - women: shorter TTNT w/ W&W & longer TTNT with R maint (biological diff?) 1/2 #lymsm

majorajay's tweet image. 15-yr F/U of my fav study by Ardeshna et al.: W&W v Rx4 low tumor burden FL
- median TTNT: NR in R maint, 14.8 yrs (!!!) in Rx4, 5.6 yrs in W&W
- 34% of W&W cohort with no tx at 15 yrs!
- women: shorter TTNT w/ W&W & longer TTNT with R maint (biological diff?)
1/2 #lymsm


radoncreview_org reposted

Seeing some logical fallacies in this debate. It not logically sound to assume that patients who progress on NAC-ICI wouldn’t have responded to upfront chemoradiotherapy.

Some intriguing data and personal reflections to contribute to this fantastic discussion. Around 10-20% of patients shuttled down NAC-ICI pathway didn’t proceed to resection or had R1+ margins highlight room for improvement. Many of these patients might have completed CCRT if…

jryckman3's tweet image. Some intriguing data and personal reflections to contribute to this fantastic discussion. Around 10-20% of patients shuttled down NAC-ICI pathway didn’t proceed to resection or had R1+ margins highlight room for improvement.

Many of these patients might have completed CCRT if…
jryckman3's tweet image. Some intriguing data and personal reflections to contribute to this fantastic discussion. Around 10-20% of patients shuttled down NAC-ICI pathway didn’t proceed to resection or had R1+ margins highlight room for improvement.

Many of these patients might have completed CCRT if…
jryckman3's tweet image. Some intriguing data and personal reflections to contribute to this fantastic discussion. Around 10-20% of patients shuttled down NAC-ICI pathway didn’t proceed to resection or had R1+ margins highlight room for improvement.

Many of these patients might have completed CCRT if…
jryckman3's tweet image. Some intriguing data and personal reflections to contribute to this fantastic discussion. Around 10-20% of patients shuttled down NAC-ICI pathway didn’t proceed to resection or had R1+ margins highlight room for improvement.

Many of these patients might have completed CCRT if…


radoncreview_org reposted

Also, radiotherapy can improve Child-Pugh scores from B ➡️ A. Lasley et al. Such a great paper! This fact tends to leave surgeons, IR, and med oncs equally jaw-dropped. Try dropping this fun fact at a GI tumor board near you! pubmed.ncbi.nlm.nih.gov/25899219/

radoncreview's tweet image. Also, radiotherapy can improve Child-Pugh scores from B ➡️ A. Lasley et al. Such a great paper!

This fact tends to leave surgeons, IR, and med oncs equally jaw-dropped. Try dropping this fun fact at a GI tumor board near you! 

pubmed.ncbi.nlm.nih.gov/25899219/
radoncreview's tweet image. Also, radiotherapy can improve Child-Pugh scores from B ➡️ A. Lasley et al. Such a great paper!

This fact tends to leave surgeons, IR, and med oncs equally jaw-dropped. Try dropping this fun fact at a GI tumor board near you! 

pubmed.ncbi.nlm.nih.gov/25899219/
radoncreview's tweet image. Also, radiotherapy can improve Child-Pugh scores from B ➡️ A. Lasley et al. Such a great paper!

This fact tends to leave surgeons, IR, and med oncs equally jaw-dropped. Try dropping this fun fact at a GI tumor board near you! 

pubmed.ncbi.nlm.nih.gov/25899219/

radoncreview_org reposted

Math checks out with absolute dose! HCC is a rather radiosensitive tumor. Interesting aside: A BED10 of >80 Gy with EBRT yields 80–90% local control. For context, 400 Gy in a single fraction equates to a BED10 of 16,400 Gy—yet the X-axis of this chart maxes out at 150 Gy. Of…

radoncreview's tweet image. Math checks out with absolute dose! HCC is a rather radiosensitive tumor. 

Interesting aside: A BED10 of >80 Gy with EBRT yields 80–90% local control.

For context, 400 Gy in a single fraction equates to a BED10 of 16,400 Gy—yet the X-axis of this chart maxes out at 150 Gy. Of…

Nope. You need 10% of that, in five fractions. ALARA.



radoncreview_org reposted

I've never understood Y90 dosimetry. The prescription dose in Gy is so high, ~10x EBRT and ~3x LDR Brachy, despite Y90's half-life being much shorter than prostate LDR isotopes. Why does intravascular therapy require such a massive dose? Does any biologically relevant volume…


radoncreview_org reposted

Could ensuring a minimum dose to the entire tumor be just as, or even more, critical than ≥ 400 Gy in some areas, especially for larger tumors? Also, is there a way to prospectively guarantee full shoulder coverage, and is this coverage routinely quantified with Y-90? 🧩 #HCC


Is this the most important question? @HCCLIVEConf #HCC 🧩

Could ensuring a minimum dose to the entire tumor be just as, or even more, critical than ≥ 400 Gy in some areas, especially for larger tumors? Also, is there a way to prospectively guarantee full shoulder coverage, and is this coverage routinely quantified with Y-90? 🧩 #HCC



radoncreview_org reposted

Until we get clear data - the story for larger tumors and especially MVI is that min dose does matter … I have seen tumor thrombus progress into confluence for example Until dosimetry is clear to interpret ( such as EYE90) along with positive phase 3 trial - onus is on y90…

Could ensuring a minimum dose to the entire tumor be just as, or even more, critical than ≥ 400 Gy in some areas, especially for larger tumors? Also, is there a way to prospectively guarantee full shoulder coverage, and is this coverage routinely quantified with Y-90? 🧩 #HCC



radoncreview_org reposted

Nope. You need 10% of that, in five fractions. ALARA.


radoncreview_org reposted

Thanks Jeff, I think it highlights a good pt that Riad touches upon. Y90 and SBRT dose are measured differently though both in Gy...you don't need 400 Gy to whole tumor in HCC - it's a radiosensitive histology.


Loading...

Something went wrong.


Something went wrong.